Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Ovarian Neoplasms 9Triple Negative Breast Neoplasms 8Endometrial Neoplasms 8Uterine Cervical Neoplasms 5Esophageal Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Fallopian Tube Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Small Cell Lung Carcinoma 2Recurrence 2NSCLC 2Mouth Neoplasms 2Laryngeal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Ovarian Epithelial 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Thyroid Neoplasms 1Stage III and IV Ovarian Cancer 1Squamous Non-small Cell Lung Cancer 1Solid Tumor Cancer 1Sarcoma, Kaposi 1Respiratory Tract Neoplasms 1Platinum-sensitive Relapsed Ovarian Cancer 1Platinum-Resistant Primary Peritoneal Carcinoma 1Pancreatic Intraductal Neoplasms 1PDAC - Pancreatic Ductal Adenocarcinoma 1

Interventions

fluzoparib 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Platinum-sensitive Relapsed Ovarian Cancer × Paclitaxel × Clear all
NCT06446206 2024-06-06

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

The First Hospital of Jilin University

Phase 2 Not yet recruiting
22 enrolled
Gynecologic

Platinum-sensitive Relapsed Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡